Recent Jobs

  • Senior Associate

    Regulatory Professionals
    Cambridgeshire, UK
    • FULL TIME
  • Regulatory Lead

    Regulatory Professionals
    Oxfordshire, UK
    • FULL TIME
  • Regulatory Consultant

    Regulatory Professionals
    Hertfordshire, UK
    • FULL TIME
  • Regulatory Operations Associate

    Regulatory Professionals
    Cambridgeshire, UK
    • FULL TIME
Load more listings

Make your job search easier

Create a candidate account to save jobs for later and have the latest roles and career advice emailed to you.

Register for Job Alerts

Want to see how you compare to the rest of the industry?

Enter your details to receive a complimentary copy of our salary guide delivered to your door.

Life Science Salary Guide

Create an Account

Complete your online profile and make it easier to apply for roles on the move.

Register your Details

Regulatory Professionals is one of the fastest growing global integrated regulatory outsourcing providers with a network of 20,000 pharmaceutical professionals globally. Working exclusively within the regulatory functions of Pharmaceutical, Biotechnology, Medical Device, Consumer health / OTC and Diagnostics industries.

Our integrated regulatory affairs recruitment team is there to support partner organisations of all sizes. Ranging for one regulatory consultant, to deliver a specialist project, to outsourcing functional regulatory teams of over 100+, Regulatory Professionals are able to offer global support partnered with expert local knowledge. Our capabilities also offer contract and permanent regulatory staffing services to allow a 360 degree service range for all aspects of regulatory delivery.

Our regulatory recruitment teams approach is tailored to meet the needs of our partners requirements allowing you to shift internal R&D focus to more strategic activities to improve lifecycle performance.

The benefits of Regulatory Professionals integrated teams are measured not just in the savings that could result in multi-mullion dollar cost reductions, but equally in understanding that delays in any part of the regulatory cycle affect the ability to give patients access to transformational products.

Our integrated teams support your product portfolio by giving you flexibility of resource at the peaks and troughs of the product life cycle, while ensuring you maintain control of strategic regulatory departments. This is supported by consistent, measurable and tracked metrics to maximise accountability.

To find out more about each of the regulatory areas we specialise in, take a look at the following regulatory recruitment services:

•    Regulatory Medical Devices
•    Regulatory Clinical
•    Regulatory CMC
•    Regulatory Submissions and Publishing
•    Regulatory Writing
•    Lifecycle Management

Our experienced specialist recruitment consultants are available to speak to you confidentially about our outsourcing regulatory affairs services. To find out more information or to discuss any of our regulatory vacancies, please call our specialist regulatory affairs recruitment team.

+44 (0)118 9522 797

Contact us today to find out how we can progress your career to the next level

Latest News

test tubes

NICE Patisiran approval puts Alnylam back in hATTR running

NICE recommends use of Alnylam’s Patisiran, after issuing a preliminary ‘no’ back in December 2018. The treatment is for a progressive, life-threatening disease called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), which until recently, was an area of significant unmet need in England. The drug will now provide eligible patients suffering from the disease with a treatment

Continue Reading

tablets

NICE publish draft guidance on leg ulcer infections in adults

NICE has issued a new draft antimicrobial prescribing guidance on leg ulcer infections in adults. The guidance comes amid worries that the overuse of antimicrobials is adding to a global threat of worldwide antimicrobial resistance. Recent UN report showed that if left unchecked, antimicrobial resistance could cause as many as 10 million deaths per year

Continue Reading

leukaemia cells

NICE approves Amgen’s leukaemia treatment

NICE announces the recommendation of Amgen’s blinatumomab for treating acute lymphoblastic leukaemia (ALL). The indication is for patients in first complete remission with minimal residual disease (MRD) activity of at least 0.1%. This decision to recommend the drug as a cost-effective use of NHS resources was made after the submission of new evidence from the

Continue Reading